<DOC>
	<DOCNO>NCT01260350</DOCNO>
	<brief_summary>This study ass safety tolerability sofosbuvir ( SOF ) 400 mg without ribavirin ( RBV ) and/or without pegylated interferon alfa-2a ( PEG ) subject genotype 1 , 2 3 hepatitis C ( HCV ) infection .</brief_summary>
	<brief_title>Open-Labeled Study PSI-7977 RBV With Without PEG-IFN Treatment-Naïve Patients With HCV GT2 GT3</brief_title>
	<detailed_description>Part 1 : HCV genotype 2 3 : participant receive SOF 400 mg daily weight-based RBV 12 week . Participants randomize equal proportion : PEG ( Arm 1 ) , PEG 4 week ( Arm 2 ) , PEG 8 week ( Arm 3 ) , PEG 12 week ( Arm 4 ) . Part 2 : HCV genotype 2 3 : participant receive SOF 400 mg daily ( monotherapy ) 12 week ( Arm 5 ) , SOF 400 mg daily PEG weight-based RBV 8 week ( Arm 6 ) ; HCV genotype 1 : null responder ( respond prior treatment ) receive SOF 400 mg daily weight-based RBV 12 week ( Arm 7 ) . Part 3 : HCV genotype 1 treatment-naive ( Arm 8 ) HCV genotype 2 3 treatment-experienced participant ( Arm 9 ) receive SOF 400 mg daily combination weight-based RBV 12 week . Part 4 : HCV genotype 2 3 treatment naive participant receive SOF 400 mg daily weight-based RBV 8 week ( Arm 10 ) SOF 400 mg daily 800 mg RBV 12 week ( Arm 11 ) . HCV genotype 1 null responder receive SOF 400 mg daily , ledipasvir ( LDV ) , weight base RBV 12 week ( Arm 12 ) . HCV genotype-1 treatment naive participant receive SOF 400 mg daily weight-based RBV LDV 12 week ( Arm 13 ) . Part 5 : HCV genotype 1 null responder receive SOF 400 mg daily GS-9669 500 mg daily weight-based RBV 12 week ( Arm 14 ) . HCV genotype-1 treatment naive participant receive SOF 400 mg daily GS-9669 500 mg daily weight-based RBV 12 week ( Arm 15 ) . Part 6 : HCV genotype 1 null responder Stage F4 fibrosis receive LDV/SOF FDC 12 week ( Arm 16 ) LDV/SOF FDC weight-based RBV 12 week ( Arm 17 ) . HCV genotype 2 3 treatment-naive participant receive LDV/SOF FDC 12 week ( Arm 18 ) . HCV genotype 2 3 treatment-experienced participant receive LDV/SOF FDC 12 week ( Arm 19 ) . HCV genotype 1 hemophiliac receive LDV/SOF FDC weight-based RBV 12 week ( Arm 20 ) . HCV genotype 1 treatment-naive participant receive LDV/SOF FDC weight-based RBV 6 week ( Arm 21 ) . HCV genotype 1 treatment-naive participant receive LDV/SOF FDC 6 week ( Arm 22 ) .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Chronic Genotype 2 3 HCVinfection Genotype 1 , serum HCV RNA ≥ 50,000 IU/mL Not coinfected HIV Use highly effective contraception method female childbearing potential sexually active male History clinically significant chronic liver disease Pregnant nursing female male pregnant female partner History significant drug allergy nucleoside/nucleotide analog . Participation clinical study within 3 month prior first dose Positive result significant drug use Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>PSI-7977</keyword>
	<keyword>Sofosbuvir</keyword>
	<keyword>GS-7977</keyword>
	<keyword>GS-5885</keyword>
	<keyword>GS-9669</keyword>
	<keyword>FDC</keyword>
	<keyword>ribavirin</keyword>
	<keyword>RBV</keyword>
	<keyword>Pegylated Interferon</keyword>
	<keyword>PEG-IFN</keyword>
	<keyword>Chronic Hepatitis C Infection</keyword>
	<keyword>HCV</keyword>
	<keyword>Hepatitis</keyword>
	<keyword>Genotype 1</keyword>
	<keyword>Genotype 2</keyword>
	<keyword>Genotype 3</keyword>
	<keyword>GT 1</keyword>
	<keyword>GT 2</keyword>
	<keyword>GT 3</keyword>
	<keyword>Hemophilia</keyword>
</DOC>